Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford has long been at the forefront of cardiovascular research.
After years of research, Norman Shumway, MD, PhD, and his colleagues announce in the Journal of the American Medical Association that they are ready to perform the first human heart transplantation. They only await a suitable donor. Ultimately the world's first heart transplantation was performed by Christiaan Barnard in South Africa, in December 1967.
Dr. Shumway and his surgical team perform the first successful adult human heart transplant in the United States on January 6, 1968.
Stanford pioneers methods to preserve donated organs outside the body. Stanford researchers found that an organ chilled, high-potassium electrolyte solution could be kept in good condition for hours, allowing the organ to be transported over thousands of miles that might exist between the donor and the recipient.
Philip Caves, MB, FRCS, and Margaret Billingham, MD, develop a technique to monitor rejection of the heart via endomyocardial biopsy. The technique employed a special instrument that was introduced through a large neck vein and huided into the right sided pumping chamber of the heart under fluoroscopic control. Several small pieces of the heart were removed and examined under a microscope to determine the presence of rejection. Before this technique, it was difficult to determine when a transplanted heart was being rejected until it was too late. With the development of Cave's cardiac tissue biopsy, rejection could be spotted early and stronger antirejection measures could be taken to save the heart. Dr. Billingham established a heart rejection grading system, the basis of which is still used today to guide immunosuppressive therapies for heart transplant recipients.
Dr. Norman Shumway and his colleagues establish the use of the drug cyclosporine to lower the risk of rejection after heart transplantation. Following a decade of intensive preclinical research and over a decade of clinical experience with heart transplantation by the Stanford team, the introduction of cyclosporine combined with the use of endomyocardial biopsy to diagnose rejection produced improved outcomes. Heart transplantation programs around the world began to achieve improved clinical outcome based on the twenty years of research performed by the Stanford transplant team.
The first simultaneous transplantation of both the heart and lungs was performed by Norman Shumway and Bruce Reitz on Arizona newspaper executive Mary Gohlke. Notably, the operation also was the first successful lung transplantation ever performed.
Dr. Philip Oyer surgically implants the world's first successful ventricular assist device as a bridge to transplantation. Stanford develops and implants the first left-ventricular assist device (LVAD) and uses it as a bridge to keep a patient alive until a heart becomes available for transplantation. The first LVAD was a cumbersome machine, with a four-pound battery pack, and was designed to be temporary, only keeping patients alive until an organ became available for transplant.
Stanford cardiologists are among the first group to show that certain beta-blockers can improve survival and reduce hospitalization rates in patients with heart failure.
Stanford scientists use advanced genome-sequencing technology to measure levels of donor DNA in the recipient's blood. The presence of such DNA is one of the earliest detectable signs of organ rejection.
A large, multi-center study led by Stanford physicians shows that the majority of biopsies in stable patients beyond 6 months post-transplantation can be eliminated using a non-invasive test that measures the gene expression in a patient's blood cells. Stanford's Heart Transplant Program remains the longest continually active program performing heart transplants in the world.
A new, cutting edge technique is used to successfully keep a patient with heart and lung failure alive long enough to receive a heart transplant.
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.